Systemic neurochemical fingerprinting of clinically approved and experimental 
neuropsychiatric drugs: implications for pharmacotherapy of AUD

Noori, HR

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_3249554_3

DetailsSummary

Released

Meeting Abstract

Systemic neurochemical fingerprinting of clinically approved and experimental neuropsychiatric drugs: implications for pharmacotherapy of AUD

MPS-Authors

/persons/resource/persons214538

Noori, HR
Research Group Neuronal Convergence, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Noori, H. (2020). Systemic neurochemical fingerprinting of clinically approved and experimental neuropsychiatric drugs: implications for pharmacotherapy of AUD. In 33rd European College of Neuropsychopharmacology Congress (ECNP 2020).

Cite as: https://hdl.handle.net/21.11116/0000-0006-E401-7

Abstract

There is no abstract available